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It is important to appreciate that there are key pathological differences 
between STEMI and ischemic stroke. STEMI is usually the result of 
plaque rupture and in-situ thrombosis, whereas ischemic stroke most 
often results from athero-thrombotic embolism.(6)
 The outcome of large strokes is very poor.  The reported mortality for 
untreated terminal occlusion of the internal carotid artery (ICA) is 53% 
and up to 90% for basilar artery occlusion. The vast majority of those 
who survive are left with severe neurological disability. 
STROKE : INITIAL EVALUATION                                                
Initial evaluation involves assessing the clinical defi cit according to the 
National Institute of Health Stroke Scale (NIHSS) (www.ninds.nih.gov/
doctors/NIH_Stroke_Scale.pdf). This score (0-42 with 0 being normal) 
is used to assess stroke severity and to help guide management 
decisions. Strokes can be divided into mild (NIHSS score <7), moderate 
(8-16), severe (17-24) and very severe (>24). Urgent brain imaging, 
either by CT scanning or MRI is mandatory. The primary purpose of the 
initial scan is to rule out a hemorrhagic stroke, which is managed 
differently. More sophisticated MR perfusion-diffusion or CT perfusion 
scans can be obtained to assess the size of the ischemic but still viable 
brain tissue surrounding the infarcted area (ischemic penumbra). This 
may help to predict the response to reperfusion therapy. However, 
these scans are more expensive and, more importantly, time consuming. 
Current data suggests that the majority of strokes will have a signifi cant 
ischemic penumbra within the fi rst 6 to 8 hours of stroke onset and 
may well benefi t from reperfusion therapy. (7,15)
INTRAVENOUS THROMBOLYSIS                                      
Intravenous tissue Plasminogen Activator (tPA) (0.9mg/kg, maximum 
dose 90mg) carries the strongest recommendation for patients who 
present within 3 hours of ischemic stroke onset (Class I; Level of 
Evidence A).(7) In the United States, however, only 2% of all ischemic 
stroke patients actually get this therapy,(6) mainly because patients 
present beyond the 3-hour cut off.  In the landmark NINDS Trial(2) 
comparing iv tPA to placebo in patients presenting within 3 hours of 
onset (median NIHSS score 14), 21% of the placebo group vs. 34% of 
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ABSTRACT
INTRODUCTION                                                               
Worldwide stroke is a leading cause of death and disability and was 
recently declared a national disaster in South Africa.(1) Stroke 
management depends on the type of stroke (ischemic or hemorrhagic), 
its size (large or small artery involved), and the time of presentation 
after onset. The majority of strokes (approximately 85%) are ischemic 
in nature and therefore may be amenable to reperfusion therapy. As 
with ST elevation myocardial infarction (STEMI) patients, early 
reperfusion should be the primary therapeutic strategy for ischemic 
stroke. However, the therapeutic window for intravenous (iv) 
thrombolysis is very narrow, being less than 3 hours after stroke onset.(2) 
This window can be extended for up to 6 hours for intra-arterial (ia) 
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the tPA group achieved full recovery at 3 months (P<0.05). However, 
there was no overall mortality difference. The intracerebral bleeding 
rate was 6.4% with tPA and 0.6% in placebo treated patients.  
Intravenous tPA has limited effi cacy. In a study using transcranial 
Doppler 1 hour following iv tPA given within 3 hours of stroke onset, 
complete vessel patency is obtained in only 17% of cases, with partial 
fl ow in 28% and no recanalization in over half the cases.(9) The effi cacy 
of iv tPA also depends on the site of arterial occlusion. Patency rates 
following iv tPA for terminal internal carotid artery (ICA) occlusion is 
less than 10%. It is approximately 30% for basilar and proximal middle 
cerebral artery (MCA) occlusions and 50% for mid MCA occlusions.(10) 
One-year outcome data from the NINDS trial(14) showed no benefi t 
of iv tPA in those patients with a baseline very large stroke (NIHSS 
score >20).
CATHETER-BASED THERAPY                                           
Intra-arterial Thrombolysis
The intra-arterial approach has been promoted because a high 
concentration of thrombolytic agent may be delivered into the 
thrombus. Despite the uncontrolled observation that recanalization 
rates may be higher with ia thrombolysis than with iv thrombolysis, 
clinical benefi t may be counterbalanced by delays to initiating treatment 
with the ia approach.(7)
Intra-arterial administration of at least one specifi c thrombolytic agent, 
recombinant prourokinase, appears to be of some benefi t in treatment 
of carefully selected patients with acute ischemic stroke secondary to 
occlusion of the MCA.(3) This conclusion was based on the results of a 
prospective, randomized, placebo-controlled phase III study testing the 
effectiveness of ia thrombolysis with prourokinase among patients with 
stroke of <6 hours’ duration secondary to occlusion of the MCA. In the 
primary intent-to-treat analysis, 40% of the 121 patients treated with 
recombinant prourokinase and 25% of the 59 control patients had a 
modifi ed Rankin Scale score of 0 to 2 at 90 days (P=0.04). Recanalization 
of the MCA was achieved in 66% of the patients treated with 
recombinant prourokinase and 18% of the patients in the control group 
(P<0.001). Intracranial hemorrhage with neurological deterioration 
within 24 hours of treatment occurred in 10% of patients treated with 
recombinant prourokinase and in 2% of the control group (P=0.06). 
No difference in overall death rate was seen between the 2 groups. 
The FDA has not approved the drug, and recombinant prourokinase is 
not currently available for clinical use. Extrapolation to tPA, the widely 
used iv cerebral thrombolytic drug, and to urokinase, which is chemically 
similar to the prourokinase prodrug, is based on consensus and case 
series data. Intra-arterial tPA has also been studied in combination with 
lower dose iv therapy (0.6mg/kg) with promising results warranting 
further study.(4)  
Mechanical Embolectomy
Mechanical embolectomy using the FDA approved Merci Retriever 
(Concentric Medical Mountain View, California, USA) is a new device 
used to extract the offending thrombo-embolus from large intracerebral 
vessels up to 8 hours post stroke onset.(5) It may also be used safely in 
a combination with either iv or ia tPA.(11)  
The Merci(5) and Multi Merci trials(11) were prospective, nonrandomized, 
multi-center trials which investigated the safety and effi cacy of a novel 
embolectomy device (Merci Retriever) to open occluded large 
intracranial vessels (ICA, proximal MCA, Basilar artery) up to 8 hours 
after stroke onset. In the Merci trial all patients (n = 151) were ineligible 
for thrombolysis. In the Multi Merci trial patients (n = 164) were either 
ineligible for thrombolysis or had failed thrombolysis. Median baseline 
NIHSS = 19. A vessel patency rate of 57.3% with the device alone and 
69.5% when combined with iv or ia thrombolytic was achieved.(11) 
Revascularization correlated with a good clinical outcome (Modifi ed 
FIGURE 1:  Illustration of the Merci L5 thrombectomy device removing thrombus. 
The L5 device is a helix of fl exible nitinol wire with an arcade of fi laments secured to 
the loops of the helix. This differs from the X5 and X6 Merci Retrievers by having 
fi laments and no taper to the coils. Within 8 hours of acute ischemic stroke, the 
balloon guide catheter is placed via femoral artery into the proximal internal carotid 
or vertebral artery. The blue microcatheter is advanced through the balloon guide 
catheter and placed through the occlusion using a microguidewire. The guidewire is 
then exchanged for the Retriever, which is advanced distal to the clot and several 
loops are deployed (A). The device is further deployed so as to fully ensnare the clot 
(B). Then, the proximal balloon of the guide is infl ated to prevent distal embolization, 
some torquing maneuvers are applied, and the microcatheter and Retriever are 
withdrawn together to retrieve the clot (C).








Rankin Score <2 at 90 days) in 49% of those patients who were 
successfully revascularised compared to just 9.6% where revascularization 
failed (p<0.001). Mortality at 90 days was 25% against 52% respectively 
(p<0.001) The rate of symptomatic intracerebral hemorrhage was 
9.8% in the Multi Merci trial; however, only 2.4% were sizable enough 
to cause mass effect.(11) This compared to 6.4% with iv tPA alone in 
the NINDS trial.(2) With growing experience and subtle device and 
technique modifi cations vessel patency rates of up to 83.6% are 
obtainable.(12)
Mechanical embolectomy is undergoing further analysis in the MR 
Rescue and IMS-2 trials. Both trials are randomized and will provide 
important effi cacy data with primary clinical outcomes.
In a recent meta-analysis on the impact of recanalization (spontaneous, 
post thrombolytic or mechanical) on ischemic stroke outcome,(12) 
clinical outcome at 3 months is strongly related to successful reperfusion 
(odds ratio 4.43. p<0.0001). Three month mortality was signifi cantly 
reduced in recanalized patients (odds ratio 0.24. p<0.0001). Rates of 
symptomatic hemorrhagic transformation did not differ between the 
two groups (Figure 2).
To date, the author has used the Merci Retriever in six cases (Table 1). 
Average age of 65 years, symptom duration of 4.2 hours and NIHSS 
score = 32. In one case with a proximal middle cerebral artery occlusion 
it was not possible to deploy the device due to extensive vessel 
tortuosity.  The patient was given ia tPA alone but failed to re-canalize 
and she suffered a large stroke.  The device was successfully deployed 
in the other fi ve cases (four terminal ICA occlusions (Figure 3), one 
distal basilar artery occlusion) and vessel patency of 100% was obtained. 
Intra-arterial tPA was given in all cases (total dose 5-15mg) in 
conjunction with the Merci Retriever. One patient died four days post 
procedure due to a massive stroke, while the outcome of the four 
successful patients far exceeded the expected prognosis for such large 
strokes. There were no symptomatic intracerebral hemorrhages.
BRAIN ATTACKS – IMPROVING PATIENT ACCESS TO 
CATHETER BASED THERAPY 
Early reperfusion with catheter based therapy, that is a short door-to-
balloon time, is the optimal treatment for acute myocardial infarction 
and it will most likely become the optimal treatment for selected large 
vessel acute ischemic stroke patients. Without reperfusion therapy 
these patients have a very poor prognosis. However, very few arrive 
at hospital in time for possible iv thrombolysis (<10%), which when 
given has limited effi cacy in opening large vessel occlusions (<30%). 
Mechanical embolectomy has been shown to be safe and effective up 
to 8 hours after stroke onset, thereby allowing far more severe acute 
stroke patients the option of revascularization and its proven benefi ts. 
Unfortunately there is a severe shortage of neuro-interventionalists in 
South Africa (approximately 7)(personal communication), and indeed 
worldwide. In the United States, there are only 385 interventional 
neuro-radiologists.(13) 
Clearly in order to provide a 24-hour a day, 365 days per year 
emergency stroke service a vast increase in the number of skilled 
neuro-interventionalists is required.  It has been proposed that the 
larger multi-specialty community of carotid interventionalists begin 
to fi ll this gap.(13) These specialists (cardiologists, vascular surgeons, 
FIGURE 2:  The impact of recanalization on ischemic stroke outcome: a meta analysis of 
53 studies involving 2066 patients.(12) Endpoints assessed were clinical outcome, mortality 
and hemorrhagic transformation of the infarct.


























78 F Right ICA*  4 37 Complete MCA,  Died 
  100% occlusion    partial ACAº 
51 M Left ICA  3 32 Complete  MRS  2 
  100% occlusion
66 F Left ICA  7 30 Complete MRS  3
  100% occlusion
70 F Left ICA  4 26 Complete MRS 2
  100% occlusion 
54 F Basilar artery  2 40 Complete left,  MRS 3 
  distal occlusion   partial right PCA2
72 F MCAª  5 26 Failed  Died 
  100% occlusion
Age Gender Vessel Symptom NIHSS Reperfusion Outcome
  involved duration score   
   (hr)
*Internal Carotid Artery;  ªMiddle Cerebral Artery; ºAnterior Cerebral Artery; 2Posterior Cerebral Artery
#National Institute of Health Stroke Scale (Functional grading of stroke size 0 (normal) to 42) 
¶  Modifi ed Rankin Score (0-6) @ 90 days (Functional grading of stroke recovery with 0 normal and 
6 dead)
TABLE 1:  Patients treated by the author with the Merci Retriever
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FIGURE 3A: Cerebral angiogram, antero-posterior view, showing complete 
occlusion of the terminal portion of the left ICA.
FIGURE 3B:  Angiogram showing complete restoration of fl ow following thrombus 
extraction.
(Reproduced with permission from Abelson et al. Cardiovascular Journal of Africa, 2008; In press)
radiologists) already have the skills to cannulate the cervical vessels and 
knowledge of neuro anatomy. It must be emphasized that the 
interventionalist is merely a member of the emergency stroke team. 
A multi-disciplinary approach involving the interventionalist, neurologist, 
emergency unit physicians and radiologists is mandatory to optimize 
patient outcome in this devastating condition. 
